This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Adverum Biotechnologies Crescita futura

Criteri Future verificati 2/6

Si prevede che gli utili di Adverum Biotechnologies diminuiranno del 2.1% all'anno, mentre si prevede che il fatturato annuo crescerà del 87.4% all'anno. Si prevede che l'EPS crescerà del 21% all'anno.

Informazioni chiave

-2.1%

Tasso di crescita degli utili

20.97%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	24.4%
Tasso di crescita dei ricavi	87.4%
Rendimento futuro del capitale proprio	n/a
Copertura analitica	Good
Ultimo aggiornamento	17 Nov 2025

Aggiornamenti recenti sulla crescita futura

Recent updates

Seeking Alpha • Nov 18

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Summary Adverum Biotechnologies, Inc. achieved positive results from both the LUNA and OPTIC studies, using Ixo-vec for the treatment of patients with wet age-related macular degeneration. The phase 3 ARTEMIS study, using Ixo-vec in combination with prophylactic regimens for the treatment of patients with wet age-related macular degeneration, expected to begin 1st half of 2025. The global age-related macular degeneration market is expected to reach $19.53 billion by 2032; About 10% of all AMD patients have wet age-related macular degeneration. The company had $153 million in cash as of September 30th of 2024; enough cash to fund its operations into the 2nd half of 2025. Read the full article on Seeking Alpha

Articolo di analisi • Feb 24

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Articolo di analisi • Sep 07

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

We can readily understand why investors are attracted to unprofitable companies. For example, although Amazon.com made...

Seeking Alpha • Aug 11

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Adverum Biotechnologies press release (NASDAQ:ADVM): Q2 GAAP EPS of -$0.44 misses by $0.10. Cash, cash equivalents and short-term investments were $235.8 million as of June 30, 2022, compared to $305.2 million as of December 31, 2021. Adverum expects the June 30, 2022 cash position to fund operations into 2025. Shares -0.66% AH.

Seeking Alpha • Jul 07

Adverum gains 13% to reach three-month high after Truist upgrade

The shares of Adverum Biotechnologies (NASDAQ:ADVM) added ~13% to reach the highest level since March after Truist upgraded the clinical-stage gene therapy company to Buy from Hold noting the prospects for its wet AMD therapy ixo-vec. Wet age-related macular degeneration or wet AMD is the leading cause of blindness in people over the age of 65. The analysts led by Joon Lee cite clarity in the future development of ixo-vec, formerly known as ADVM-022 in wet AMD after the U.S. and EU regulators agreed for a Phase 2 trial for the candidate targeted at the indication. “We view it as a materially derisking event for wAMD and other future ocular indications based on the AAV.7m8 chassis,” the analysts wrote referring to the vector capsid used in the gene therapy candidate. The analysts expect a series of data readouts in 2023 and point out that Adverum (ADVM) has extended its cash runway by one year to 2025 following the restructuring. The price target raised to $4 from $3 is in line with the current average price target for the stock on Wall Street.

Articolo di analisi • May 12

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Articolo di analisi • Jul 17

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Articolo di analisi • Apr 06

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Articolo di analisi • Feb 13

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

We'd be surprised if Adverum Biotechnologies, Inc. ( NASDAQ:ADVM ) shareholders haven't noticed that the President...

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:ADVM - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Utili	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	N/A	-203	-238	N/A	3
12/31/2026	0	-194	-215	-211	6
12/31/2025	0	-195	-187	-171	6
9/30/2025	N/A	-185	-138	-138	N/A
6/30/2025	1	-169	-132	-131	N/A
3/31/2025	1	-151	-113	-112	N/A
12/31/2024	1	-131	-93	-92	N/A
9/30/2024	1	-119	-86	-86	N/A
6/30/2024	N/A	-119	-89	-88	N/A
3/31/2024	N/A	-120	-93	-92	N/A
12/31/2023	4	-122	-92	-91	N/A
9/30/2023	4	-126	-89	-88	N/A
6/30/2023	4	-133	-97	-96	N/A
3/31/2023	4	-146	-109	-102	N/A
12/31/2022	N/A	-155	-120	-108	N/A
9/30/2022	N/A	-156	-131	-115	N/A
6/30/2022	N/A	-154	-130	-109	N/A
3/31/2022	N/A	-155	-133	-114	N/A
12/31/2021	8	-146	-123	-108	N/A
9/30/2021	8	-149	-116	-104	N/A
6/30/2021	8	-138	-115	-105	N/A
3/31/2021	8	-123	-97	-88	N/A
12/31/2020	N/A	-118	-91	-79	N/A
9/30/2020	N/A	-99	-91	-72	N/A
6/30/2020	0	-87	-77	-55	N/A
3/31/2020	0	-73	-71	-50	N/A
12/31/2019	0	-64	-68	-49	N/A
9/30/2019	0	-61	-58	-47	N/A
6/30/2019	1	-66	N/A	-54	N/A
3/31/2019	1	-70	N/A	-54	N/A
12/31/2018	2	-73	N/A	-54	N/A
9/30/2018	2	-72	N/A	-53	N/A
6/30/2018	2	-65	N/A	-47	N/A
3/31/2018	2	-57	N/A	-47	N/A
12/31/2017	2	-56	N/A	-45	N/A
9/30/2017	2	-64	N/A	-42	N/A
6/30/2017	2	-64	N/A	-41	N/A
3/31/2017	2	-114	N/A	-38	N/A
12/31/2016	1	-114	N/A	-38	N/A
9/30/2016	2	-105	N/A	-39	N/A
6/30/2016	2	-105	N/A	-39	N/A
3/31/2016	2	-53	N/A	-40	N/A
12/31/2015	2	-47	N/A	-35	N/A
9/30/2015	2	-44	N/A	-31	N/A
6/30/2015	1	-38	N/A	-27	N/A
3/31/2015	1	-36	N/A	-12	N/A
12/31/2014	1	-29	N/A	-6	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ADVM rimarrà non redditizia nei prossimi 3 anni.

Guadagni vs Mercato: Si prevede che ADVM rimarrà non redditizia nei prossimi 3 anni.

Guadagni ad alta crescita: Si prevede che ADVM rimarrà non redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ADVM ( 87.4% all'anno) crescerà più rapidamente del mercato US ( 12.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ADVM ( 87.4% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di ADVM è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/12/10 01:41
Prezzo dell'azione a fine giornata	2025/12/08 00:00
Utili	2025/09/30
Utili annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina GitHub; abbiamo anche delle guide su come utilizzare i nostri report e dei tutorial su YouTube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Adverum Biotechnologies, Inc. è coperta da 12 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Graig Suvannavejh	Goldman Sachs
Biren Amin	Jefferies LLC
Mani Foroohar	Leerink Partners LLC

This company has been acquired

Adverum Biotechnologies Crescita futura

Criteri Future verificati 2/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates fall by 99%

Price target decreased by 44% to US$11.00

Consensus EPS estimates fall by 11%

Price target decreased by 24% to US$19.75

Price target decreased to US$3.67

Price target decreased to US$3.67

Recent updates

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell Microcap Growth Index

Consensus revenue estimates fall by 99%

New major risk - Financial position

Price target decreased by 44% to US$11.00

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire Adverum Biotechnologies, Inc. (NasdaqCM:ADVM) for $80.2 million.

Consensus EPS estimates fall by 11%

Adverum Biotechnologies, Inc. Announces Completion of Screening for Pivotal Phase 3 ARTEMIS Trial of Ixo-Cov for Wet Age-Related Macular Degeneration

Adverum Biotechnologies, Inc. announced that it has received $10 million in funding from Frazier Life Sciences Management, LP

Price target decreased by 24% to US$19.75

Adverum Biotechnologies, Inc.(NasdaqCM:ADVM) dropped from Russell 3000 Value Index

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2025

Adverum Biotechnologies, Inc. Auditor Raises 'Going Concern' Doubt

Adverum Biotechnologies, Inc. announced delayed annual 10-K filing

Adverum Biotechnologies, Inc. Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD

Adverum Biotechnologies Announces Positive 52-Week Luna and 4-Year Optic Results, and Provides Key Pivotal Program Design Elements

Adverum: Ixo-Vec Could Reduce Treatment Burden For Wet-AMD Patients

Adverum Biotechnologies, Inc. Appoints Jason L. Mitchell as Chief Commercial Officer

Adverum Biotechnologies Announces Fda Regenerative Medicine Advanced Therapy (Rmat) Designation Granted for Ixo-Vec for the Treatment of Wet Amd

Adverum Biotechnologies, Inc. Presents Positive Ixo-vec Clinical Data from the 26-Week Interim Analysis of the LUNA Phase 2 Trial at the 2024 ASRS Annual Meeting

Adverum Biotechnologies, Inc. Announces Executive Changes

Adverum Biotechnologies, Inc., Annual General Meeting, Jun 17, 2024

Adverum Biotechnologies, Inc. announced that it has received $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Announces Positive Preliminary Efficacy and Safety Data from Luna Phase 2 Trial of Ixo-Cov in Patients with Wet AMD

Adverum Biotechnologies, Inc. Announces Stipulation and Agreement of Settlement

Adverum Biotechnologies, Inc. announced that it expects to receive $127.5 million in funding from a group of investors

Adverum Biotechnologies, Inc. Appoints Romuald Corbau as Chief Scientific Officer and Member of Executive Committee

Adverum Biotechnologies Receives a Letter from the Nasdaq Listing Qualifications Staff of the Nasdaq Stock Market

Adverum Biotechnologies, Inc. Appoints C. David Nicholson to the Board of Directors

Adverum Biotechnologies, Inc. Announces Positive Aflibercept Protein Level Data from the Luna Phase 2 Trial

Adverum Biotechnologies, Inc. Appoints R. Andrew Andy Ramelmeier as Chief Technology Officer

Adverum Biotechnologies, Inc. Completes Enrollment of Phase 2 LUNA Trial in Wet AMD

Adverum Biotechnologies Receives Nasdaq Notice on Regained Compliance with Minimum Bid Price Requirement

Adverum Biotechnologies, Inc. Announces Resignation of Richard Beckman as Chief Medical Officer

Adverum Biotechnologies, Inc. Receives Approval from the Listing Qualifications Department of Nasdaq to Transfer the Listing of Common Stock from Nasdaq Global Market to Nasdaq Capital Market

Adverum Biotechnologies, Inc. Presents Nonclinical Data in Support of Ixo-vec’s Phase 2 Clinical Development at ASGCT 2023 Annual Meeting

We're Keeping An Eye On Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Price target decreased to US$3.67

Price target decreased to US$3.67

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Adverum Biotechnologies GAAP EPS of -$0.44 misses by $0.10

Price target increased to US$4.33

Adverum gains 13% to reach three-month high after Truist upgrade

We Think Adverum Biotechnologies (NASDAQ:ADVM) Needs To Drive Business Growth Carefully

Price target increased to US$4.33

High number of new directors

Independent Director recently sold US$109k worth of stock

Price target increased to US$4.33

Chief Business Officer & Acting CFO Christopher DeRespino has left the company

Price target decreased to US$3.57

Consensus revenue estimates increase to US$6.00m

Consensus forecasts updated

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Price target decreased to US$17.11

We're Not Very Worried About Adverum Biotechnologies' (NASDAQ:ADVM) Cash Burn Rate

Independent Chairman recently bought US$99k worth of stock

New 90-day low: US$10.55

Analysts lower revenue estimates to US$230.0k

Don't Ignore The Fact That This Insider Just Sold Some Shares In Adverum Biotechnologies, Inc. (NASDAQ:ADVM)

New 90-day high: US$14.36

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Fonti dei dati

Modello di analisi e Snowflake

Metriche di settore e industriali